Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-512646-42-00Phase 2Completed
- Sponsor
- Immunovant, Inc.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 2, randomised, triple-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Batoclimab with Placebo (2 arms). Primary endpoint: Relapse-free proportion at Week 36 (Period 2 / Cohort A). Started Aug 2024; status: completed.
02
Drugs
batoclimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2024-512646-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512646-42-00.